The Hemann and Walker labs previously discovered that the compound JH-RE-06 enhanced the tumor-shrinking effects of DNA-damaging chemotherapies. While they expected JH-RE-06 to amplify programmed cell death induced by DNA damage, two studies appearing in PNAS showed that JH-RE-06, or genetically ablating the pathway targeted by JH-RE-06, instead puts tumor cells in a permanently dormant state known as senescence. Because senescent cells are often cleared by immune cells, these findings suggest a complementary approach to traditional chemotherapies.